Lauren Tanabe on Muck Rack

Lauren Tanabe

As seen in: Elemental, Nature, The Washington Post, Slate, Stuff.co.nz, New Zealand Herald, Mental Floss, Independent Online, MindBodyGreen, MYSA and
Writer, mother, recovering academic, former NYer, lover of coffee, things that distract children, Bylines @slate @washingtonpost @elemental #binders

Get in touch with Lauren

Contact Lauren, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer

|
By Michael Flynn, Brianna Rivera, Lauren Tanabe, Paul Stemmer, Li-Mei Chen, Karl Chai, Joseph G. Lundgren, Ani R. Winkler, Karin List
| Nature Verified
Abstract Serine proteases play multifaceted roles in cancer, affecting tumor formation, progression, and metastasis. While most serine proteases studied act as tumor promoters by remodeling the extracellular matrix and activating signaling pathways, others can function as tumor suppressors. Prostasin is a glycosylphosphatidylinositol-anchored serine protease that is expressed in epithelial tissues, including the ductal epithelium of the breast.
Open in Who Shared Issue with article?

Decoding the Tumor Ecosystem

|
By Lauren Tanabe
| Biocompare Verified
For decades, studying the tumor microenvironment (TME) meant cataloguing its contents. But a new generation of technology is moving beyond characterization and toward predicting how tumors will behave and who will respond to treatment. The TME is more than a backdrop for cancer growth. It is a dynamic, densely populated ecosystem in which immune cells, stromal cells, blood vessels, and even microorganisms collectively determine whether a tumor thrives, spreads, or yields to therapy.
Open in Who Shared Issue with article?

The Evolving Landscape of Cell and Gene Therapy

|
By Lauren Tanabe
| Biocompare Verified
Cell and gene therapies have evolved from experimental concepts into a maturing therapeutic class, with dozens of approved products worldwide and a robust late-stage pipeline. Once viewed as bespoke solutions for rare diseases, they are now confronting the practical realities of scale, safety, and durability as they expand into broader clinical use.
Open in Who Shared Issue with article?
See all 36 licensed articles (38 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified